Rep. Robert Bresnahan, Jr. Buys STERIS plc (NYSE:STE) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of STERIS plc (NYSE:STE). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in STERIS stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

STERIS Stock Performance

STE stock opened at $222.99 on Friday. The company has a market capitalization of $21.91 billion, a P/E ratio of 47.34 and a beta of 0.92. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The company has a 50-day simple moving average of $222.51 and a 200 day simple moving average of $221.30. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. Sell-side analysts predict that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 21st. Investors of record on Thursday, February 20th were paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date was Thursday, February 20th. STERIS’s dividend payout ratio is currently 48.41%.

Wall Street Analysts Forecast Growth

STE has been the subject of several research analyst reports. JMP Securities restated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday, February 6th. Stephens reissued an “overweight” rating and issued a $240.00 price target on shares of STERIS in a report on Thursday, February 6th. Finally, Piper Sandler lifted their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average target price of $258.75.

Institutional Investors Weigh In On STERIS

Hedge funds have recently modified their holdings of the stock. Avalon Trust Co purchased a new stake in STERIS during the fourth quarter valued at about $30,000. Human Investing LLC purchased a new stake in shares of STERIS in the 4th quarter valued at approximately $31,000. Anfield Capital Management LLC lifted its position in shares of STERIS by 100.0% in the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 91 shares in the last quarter. Central Pacific Bank Trust Division boosted its stake in STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 76 shares during the period. Finally, Manchester Capital Management LLC grew its position in STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 137 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.